bioAffinity Technologies prices $4.8 million public offering

bioAffinity Technologies Inc. (NASDAQ: BIAF, BIAFW) announced it has priced a public offering for aggregate gross proceeds of $4.8 million, before deducting agent fees and other expenses.

The biotechnology company, which focuses on noninvasive tests for early-stage cancer detection, will offer 1,921,799 shares of common stock or pre-funded warrants at $2.50 per share. Pre-funded warrants are priced at $2.493 each and will be exercisable for one share of common stock with an exercise price of $0.007 per share.

The offering is expected to close on or about September 30, 2025, subject to customary closing conditions. WallachBeth Capital LLC is serving as the sole placement agent for the transaction.

The securities are being offered under a registration statement on Form S-1 that was previously filed with the Securities and Exchange Commission and declared effective. A final prospectus will be filed with the SEC and made available on the agency's website.

bioAffinity Technologies develops noninvasive diagnostic tests for early-stage cancer and lung diseases. The company's first product, CyPath Lung, is marketed as a Laboratory Developed Test through its subsidiary Precision Pathology Laboratory Services.

You May Also Be Interested In